yeah - he has done the opposite this time. Previously, he always mentioned lots of interests with global pharmaceutical companies for trofinitide and ROW negotiations in each of the update. He has gone completely quiet on that front in this annual report which suggests to me something more serious is happening in the background
NEU Price at posting:
$19.36 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)